TN2013000390A1 - Bispecific binding molecules binding to vegf and ang2 - Google Patents

Bispecific binding molecules binding to vegf and ang2

Info

Publication number
TN2013000390A1
TN2013000390A1 TNP2013000390A TN2013000390A TN2013000390A1 TN 2013000390 A1 TN2013000390 A1 TN 2013000390A1 TN P2013000390 A TNP2013000390 A TN P2013000390A TN 2013000390 A TN2013000390 A TN 2013000390A TN 2013000390 A1 TN2013000390 A1 TN 2013000390A1
Authority
TN
Tunisia
Prior art keywords
ang2
vegf
binding
binding molecules
bispecific
Prior art date
Application number
TNP2013000390A
Other languages
English (en)
Inventor
Andreas Gschwind
Rene Georg Ott
Joachim Boucneau
Marie-Ange Buyse
Erik Depla
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45895502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000390(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TN2013000390A1 publication Critical patent/TN2013000390A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2013000390A 2011-04-01 2013-09-26 Bispecific binding molecules binding to vegf and ang2 TN2013000390A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11160921 2011-04-01
PCT/EP2012/055901 WO2012131078A1 (fr) 2011-04-01 2012-03-30 Molécules de liaison bispécifiques se liant à vegf et à ang2

Publications (1)

Publication Number Publication Date
TN2013000390A1 true TN2013000390A1 (en) 2015-01-20

Family

ID=45895502

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000390A TN2013000390A1 (en) 2011-04-01 2013-09-26 Bispecific binding molecules binding to vegf and ang2

Country Status (36)

Country Link
US (4) US9527925B2 (fr)
EP (2) EP3144322A3 (fr)
JP (2) JP6023786B2 (fr)
KR (1) KR101907572B1 (fr)
CN (2) CN105820243A (fr)
AP (1) AP2013007085A0 (fr)
AR (1) AR085984A1 (fr)
AU (2) AU2012237234B2 (fr)
BR (1) BR112013025304B1 (fr)
CA (1) CA2827817C (fr)
CL (1) CL2013002623A1 (fr)
CO (1) CO6801639A2 (fr)
CY (1) CY1118339T1 (fr)
DK (1) DK2694546T3 (fr)
EA (2) EA025148B1 (fr)
EC (1) ECSP13013001A (fr)
ES (1) ES2606302T3 (fr)
HK (1) HK1225400A1 (fr)
HR (1) HRP20161689T1 (fr)
HU (1) HUE030148T2 (fr)
IL (1) IL227936B (fr)
LT (1) LT2694546T (fr)
MA (1) MA34979B1 (fr)
MX (2) MX343440B (fr)
MY (1) MY171007A (fr)
PE (1) PE20140448A1 (fr)
PH (1) PH12013502044A1 (fr)
PL (1) PL2694546T3 (fr)
PT (1) PT2694546T (fr)
RS (1) RS55361B1 (fr)
SG (2) SG10201602373TA (fr)
SI (1) SI2694546T1 (fr)
TN (1) TN2013000390A1 (fr)
UA (1) UA114707C2 (fr)
UY (1) UY33998A (fr)
WO (1) WO2012131078A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
SI2831111T1 (sl) * 2012-03-30 2019-06-28 Boehringer Ingelheim International Gmbh Ang2-vezavne molekule
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
KR20150060686A (ko) * 2012-09-28 2015-06-03 베링거 인겔하임 인터내셔날 게엠베하 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF 제제를 포함하는 약제학적 조합물
JP2015532272A (ja) * 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
TWI632160B (zh) * 2015-01-16 2018-08-11 中央研究院 具有標的部分及效應部分的分子構建體
AR103477A1 (es) 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
CA3255406A1 (fr) 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Polypeptides de liaison tnf-alpha
WO2016156468A1 (fr) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
CA2992660A1 (fr) * 2015-07-29 2017-02-02 Allergan, Inc. Anticorps contenant seulement une chaine lourde contre ang-2
EP3334762A1 (fr) 2015-08-14 2018-06-20 Allergan, Inc. Anticorps à chaîne lourde uniquement contre le pgdf
PE20181363A1 (es) * 2015-09-23 2018-08-27 Genentech Inc Variantes optimizadas de anticuerpos anti-vegf
LT3374392T (lt) * 2015-11-13 2022-01-25 Ablynx Nv Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai
UA122079C2 (uk) 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
IL264961B2 (en) 2016-08-23 2025-02-01 Medimmune Ltd Antibodies against VEGF–A and their uses
US10836819B2 (en) 2016-08-23 2020-11-17 Medimmune Limited Anti-VEGF-A and anti-ANG2 antibodies and uses thereof
JP2020502126A (ja) * 2016-12-14 2020-01-23 プロジェニティ， インコーポレイテッド 消化管疾病のｊａｋ阻害薬による治療
RU2648164C1 (ru) * 2016-12-19 2018-03-22 Федеральное государственное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Селективный бифункциональный препарат на основе фрагментов одноцепочечных антител верблюжьих, нацеленный на опухолевые рецепторы cd47/erbb2, предназначенный для терапии злокачественных новообразований
WO2018114728A1 (fr) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Polythérapie par anticorps bispécifique anti-ang2/vegf et anticorps bispécifique anti-her2
WO2018128939A1 (fr) 2017-01-05 2018-07-12 Gensun Biopharma Inc. Antagonistes de régulateur de point de contrôle
EP3630816B1 (fr) 2017-05-31 2024-03-20 Boehringer Ingelheim International GmbH Polypeptides antagonistes de la signalisation wnt dans des cellules tumorales
US11198726B2 (en) * 2017-06-02 2021-12-14 Boerhinger Ingelheim International Gmbh Anti-cancer combination therapy
SG11202006712XA (en) 2018-02-06 2020-08-28 Hoffmann La Roche Treatment of ophthalmologic diseases
WO2019246273A1 (fr) * 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un jak ou un autre inhibiteur de kinase
US10597453B2 (en) 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
EP3886946A1 (fr) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Dispositifs et procédés pour l'administration précise de doses
US12559552B2 (en) 2019-06-21 2026-02-24 Sorriso Pharmaceuticals, Inc. IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
CA3144567A1 (fr) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
CN114340735B (zh) 2019-06-28 2024-11-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
IL293725A (en) 2019-12-11 2022-08-01 Cullinan Oncology Inc Anti-cd19 antibodies and multispecific binding proteins
IL293780A (en) * 2019-12-11 2022-08-01 Cullinan Man Inc Anti-serum albumin antibodies
WO2021155151A1 (fr) * 2020-01-29 2021-08-05 The Methodist Hospital System Ligands multivalents ciblant des récepteurs de surface cellulaire et plateforme de mesure de force pour leur fabrication
WO2021209458A1 (fr) 2020-04-14 2021-10-21 Ares Trading S.A. Traitement combiné du cancer
WO2022010273A1 (fr) 2020-07-07 2022-01-13 주식회사 카나프테라퓨틱스 Protéines de fusion comprenant un inhibiteur de la voie du complément et leur utilisation
US12064421B2 (en) 2020-11-02 2024-08-20 Boehringer Ingelheim International Gmbh Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
EP4019548A1 (fr) * 2020-12-23 2022-06-29 Vrije Universiteit Brussel Vhh anti lag3 et leurs utilisations
KR20230142838A (ko) * 2021-02-10 2023-10-11 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 항-vegf 항체 및 이의 용도
CA3208389A1 (fr) * 2021-02-19 2022-08-25 Ignacio ASIAL Molecules de liaison a vegfa
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
WO2022256820A1 (fr) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Antagonistes multispécifiques
IL309035A (en) * 2021-06-04 2024-02-01 Innovent Biologics Suzhou Co Ltd A bispecific binding molecule that binds to VEGF and ANG2 and its use
CN118043350A (zh) * 2021-08-13 2024-05-14 信达生物制药(苏州)有限公司 抗vegf a和vegf c双特异性抗体及其用途
CA3231417A1 (fr) * 2021-09-10 2023-03-16 Jian Shi Anticorps anti-ang2, son procede de preparation et son utilisation
CU24770B1 (es) * 2021-12-15 2025-09-01 Ct Ingenieria Genetica Biotecnologia Polipéptidos que se unen al factor de crecimiento del endotelio vascular y al factor básico de crecimiento de fibroblastos
KR20230105972A (ko) 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
CN119790077A (zh) * 2022-09-14 2025-04-08 寻济生物科技（北京）有限公司 一种抗vegfa融合蛋白及其制备方法和应用
AU2023340044A1 (en) 2022-09-14 2025-04-03 Quaerite Biopharm Research (Beijing) Co., Ltd. Anti-vegfa antibody or antigen-binding fragment thereof and use thereof
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN120322464A (zh) * 2022-12-01 2025-07-15 信达生物制药(苏州)有限公司 三特异性融合蛋白及其用途
IL321122A (en) * 2022-12-01 2025-07-01 Innovent Biologics Suzhou Co Ltd Formulations containing dual-specific binding molecules that bind VEGF and ANG2 and their uses
WO2024178730A1 (fr) * 2023-03-02 2024-09-06 清华大学 Médicament protéique cristallisable anti-vegf intravitréen pour inhiber la néovascularisation choroïdienne
WO2025111816A1 (fr) * 2023-11-28 2025-06-05 Eluminex Biosciences Limited Protéines de fusion multispécifiques ciblant des facteurs angiogéniques, inflammatoires et/ou fibrotiques
CN120025456B (zh) * 2024-03-13 2025-11-07 寻济生物科技（北京）有限公司 一种抗vegfa融合构建体及其制备方法和应用
WO2025219504A1 (fr) 2024-04-19 2025-10-23 F. Hoffmann-La Roche Ag Traitement de maladies ophtalmologiques
WO2026037352A1 (fr) * 2024-08-13 2026-02-19 长春金赛药业有限责任公司 Protéine de fusion fc se liant simultanément à vegf et ang-2 et son utilisation
CN121405805B (zh) * 2025-09-25 2026-04-28 首都医科大学附属北京朝阳医院 一种抗人源整合素cd103纳米抗体与应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US5408535A (en) 1993-09-07 1995-04-18 Miles Inc. Video test strip reader and method for evaluating test strips
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
EP2213743A1 (fr) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Protéines de fusion d'albumine
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
WO2003059934A2 (fr) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Proteines de fusion d'albumine
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2003217852A1 (en) 2002-03-01 2003-09-16 Ball Horticultural Company Lis promoter for expression of transgenes in floral tissues
AU2003267563A1 (en) 2002-09-10 2004-04-30 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
US20050043220A1 (en) 2002-11-08 2005-02-24 Guyer David R. Methods and compositions for treating macular degeneration
EP1558645B1 (fr) 2002-11-08 2011-07-27 Ablynx N.V. Anticorps a domaine unique stabilises dans une composition pharmaceutique pour inhalation
WO2004041863A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique diriges contre un interferon gamma et leurs utilisations
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2005040219A1 (fr) 2003-10-28 2005-05-06 Novo Nordisk A/S Peptides fixant la laminine-5 gamma-2, compositions associees et leurs applications
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
WO2006040153A2 (fr) 2004-10-13 2006-04-20 Ablynx N.V. Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US20060134111A1 (en) 2004-12-17 2006-06-22 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US8188223B2 (en) * 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
WO2007053186A2 (fr) 2005-05-31 2007-05-10 Labnow, Inc. Méthodes et compositions en rapport avec la détermination et l’utilisation de la numération de globules blancs
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009507796A (ja) 2005-09-01 2009-02-26 バスジーン セラピューティクス， インコーポレイテッド デルタ様リガンド４のモジュレーターの利用及び同定方法
JPWO2007043109A1 (ja) 2005-09-30 2009-04-16 富士通株式会社 情報記憶装置
EP1962903B1 (fr) * 2005-12-15 2013-03-13 MedImmune Limited Combinaison d'un antagoniste de l'angiopoietine 2 et d'un antagoniste du vegf-a et/ou du kdr et/ou du fltl pour le traitement du cancer
CA2630839C (fr) 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Procedes therapeutiques pour l'inhibition de croissance tumorale avec des antagonistes dll4
EP2441838A3 (fr) 2006-01-24 2013-07-10 Domantis Limited Protéines de fusion contenant des jonctions naturelles
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US7570881B2 (en) 2006-02-21 2009-08-04 Nokia Corporation Color balanced camera with a flash light unit
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
NZ572177A (en) 2006-06-06 2012-02-24 Genentech Inc Anti-dll4 antibodies and methods using same
EP2029159A2 (fr) 2006-06-06 2009-03-04 Genentech, Inc. Compositions et procédés destinés à moduler le développement vasculaire
HRP20130271T1 (hr) 2006-08-07 2013-04-30 Regeneron Pharmaceuticals, Inc. Upotreba dii4 antagonista kod ishemijskih ozljeda ili vaskularne insuficijencije
WO2008020079A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
ATE536369T1 (de) 2006-10-11 2011-12-15 Ablynx Nv Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
JP2010507594A (ja) 2006-10-20 2010-03-11 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2121757A2 (fr) 2007-02-21 2009-11-25 Ablynx N.V. Séquences d'acides aminés dirigées contre le facteur de croissance de l'endothélium vasculaire et polypeptides comprenant ces séquences, pour le traitement de troubles et de maladies se caractérisant par une angiogenèse pathologique ou une néovascularisation
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
JP2010528647A (ja) 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
CA2688433A1 (fr) 2007-06-06 2008-12-11 Domantis Limited Procede de selection de polypeptides resistant aux proteases
EP2014680A1 (fr) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Dérivés d'anticorps bi-spécifiques ou tri-spécifiques trivalents, recombinants, à simple chaîne
JP2011500086A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
MX2010005603A (es) 2007-11-26 2010-08-02 Bayer Schering Pharma Ag Anticuerpos antimesotelina y usos de los mismos.
WO2009095489A2 (fr) 2008-02-01 2009-08-06 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
GB2470328A (en) 2008-03-05 2010-11-17 Ablynx Nv Novel antigen binding dimer complexes, methods of making and uses thereof
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
LT2285408T (lt) 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
TWI487712B (zh) 2008-09-03 2015-06-11 建南德克公司 多重特異性抗體
AU2009294415B2 (en) 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AU2009324354B2 (en) 2008-12-10 2016-04-14 Ablynx Nv Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
RU2578023C2 (ru) 2009-01-13 2016-03-20 Эф-Ай-Оу Корпорейшн Портативный диагностический прибор и способ его применения с электронным устройством и диагностическим картриджем при диагностическом экспресс-исследовании
WO2010124009A2 (fr) 2009-04-21 2010-10-28 Schering Corporation Anticorps anti-vegf entièrement humains et méthodes d'utilisation de ceux-ci
WO2010129304A2 (fr) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
EP2443150B1 (fr) 2009-06-17 2015-01-21 AbbVie Biotherapeutics Inc. Anticorps anti-vegf et leurs utilisations
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
TWI619509B (zh) 2010-02-23 2018-04-01 建南德克公司 治療先前未經治療之ⅲ期或ⅳ期卵巢癌、輸卵管癌或原發性腹膜癌之卡鉑、太平洋紫杉醇與抗-vegf抗體之組合
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2012012499A1 (fr) 2010-07-20 2012-01-26 Nurx Pharmaceuticals, Inc. Système de lecteur optique
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
MX2013004979A (es) 2010-11-02 2013-07-30 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
WO2012166287A1 (fr) 2011-05-27 2012-12-06 Novartis Ag Méthode de traitement de troubles de la vision
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
SI2831111T1 (sl) * 2012-03-30 2019-06-28 Boehringer Ingelheim International Gmbh Ang2-vezavne molekule
US9292583B2 (en) * 2012-11-27 2016-03-22 Google Inc. Method of displaying search results

Also Published As

Publication number Publication date
AU2017200237B2 (en) 2018-05-17
EA201600338A1 (ru) 2016-09-30
US20130078248A1 (en) 2013-03-28
ECSP13013001A (es) 2013-12-31
KR101907572B1 (ko) 2018-10-15
SG10201602373TA (en) 2016-05-30
EP2694546A1 (fr) 2014-02-12
MX337543B (es) 2016-03-10
MX2013010949A (es) 2014-06-06
PL2694546T3 (pl) 2017-03-31
UA114707C2 (uk) 2017-07-25
EP2694546B1 (fr) 2016-09-21
EA036746B1 (ru) 2020-12-16
JP6023786B2 (ja) 2016-11-09
BR112013025304A2 (pt) 2017-06-06
JP2017023152A (ja) 2017-02-02
UY33998A (es) 2012-09-28
WO2012131078A1 (fr) 2012-10-04
US9527925B2 (en) 2016-12-27
AU2017200237A1 (en) 2017-02-02
CN103562222A (zh) 2014-02-05
SG193561A1 (en) 2013-11-29
JP2014515602A (ja) 2014-07-03
SI2694546T1 (sl) 2017-01-31
CY1118339T1 (el) 2017-06-28
IL227936B (en) 2018-06-28
DK2694546T3 (en) 2016-12-05
EP3144322A2 (fr) 2017-03-22
US20200010569A1 (en) 2020-01-09
IL227936A0 (en) 2013-09-30
ES2606302T3 (es) 2017-03-23
BR112013025304B1 (pt) 2022-10-11
CN103562222B (zh) 2016-04-06
AP2013007085A0 (en) 2013-08-31
AR085984A1 (es) 2013-11-13
MX343440B (es) 2016-11-07
CA2827817C (fr) 2020-12-15
NZ614249A (en) 2015-05-29
HUE030148T2 (en) 2017-04-28
EA201301108A1 (ru) 2014-03-31
CN105820243A (zh) 2016-08-03
CA2827817A1 (fr) 2012-10-04
US11161916B2 (en) 2021-11-02
RS55361B1 (sr) 2017-03-31
US20220017642A1 (en) 2022-01-20
AU2012237234B2 (en) 2016-10-20
CO6801639A2 (es) 2013-11-29
US20170247475A1 (en) 2017-08-31
PH12013502044A1 (en) 2013-12-16
CL2013002623A1 (es) 2014-02-14
MY171007A (en) 2019-09-23
EP3144322A3 (fr) 2017-05-31
HK1225400A1 (zh) 2017-09-08
EA025148B1 (ru) 2016-11-30
KR20140018317A (ko) 2014-02-12
PT2694546T (pt) 2016-12-28
PE20140448A1 (es) 2014-04-13
MA34979B1 (fr) 2014-03-01
US10414828B2 (en) 2019-09-17
HK1190412A1 (zh) 2014-07-04
AU2012237234A1 (en) 2013-09-05
HRP20161689T1 (hr) 2017-02-24
JP6297657B2 (ja) 2018-03-20
LT2694546T (lt) 2016-11-10

Similar Documents

Publication Publication Date Title
TN2013000390A1 (en) Bispecific binding molecules binding to vegf and ang2
IN2014DN06904A (fr)
TN2012000144A1 (en) Dll4-binding molecules
PH12013500410B1 (en) Vegf-binding molecules
TN2012000145A1 (en) Bispecific binding molecules for anti-angiogenesis therapy
WO2014004549A3 (fr) Protéines de liaison anti-mésothéline
TN2013000389A1 (en) BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2
PH12014502527B1 (en) St2 antigen binding proteins